| Returns | 1W : -2.8% , 1M : -10.8%,1Y : 62.7% |
| LT : |
Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Average |
| ST : |
Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
| Peers & Returns | 1W | 1M | 1Y |
| ALEMBIC PHARMACEUTICALS LTD | -2.8% | -10.8% | 62.7% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | -4.2% | -3% | 31% |
| DR REDDYS LABORATORIES LTD | -3.3% | -5.7% | 67.8% |
| DIVIS LABORATORIES LTD | -3.4% | -7.5% | 86.8% |
| CIPLA LTD | 1.1% | 1.5% | 82.7% |
| BIOCON LTD | -16% | -18.9% | 30% |
| AUROBINDO PHARMA LTD | 3.2% | 5.7% | 99.2% |
| LUPIN LTD | -1.2% | 9.2% | 46.2% |
| TORRENT PHARMACEUTICALS LTD | -2.8% | -5.2% | 29.4% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
21.66
P/E Calculated based on EPS of 43.97
[ Mar2020 - Consolidated Results ] 5.58
P/B Calculated based on Book Value of 170.79
[ Mar2020 - Consolidated Results ] 3.59
P/S Calculated based on Revenues of 5214.38 Cr
[ TTM - Consolidated Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
10% 16% 16% |
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
